HUP0104206A2 - (7alfa,17alfa)-17-Hidroxi-7-metil-19-nor-17-pregn-5(10)-en-20-in-3-ont tartalmazó nagy tisztaságú készítmény és eljárás előállítására - Google Patents

(7alfa,17alfa)-17-Hidroxi-7-metil-19-nor-17-pregn-5(10)-en-20-in-3-ont tartalmazó nagy tisztaságú készítmény és eljárás előállítására

Info

Publication number
HUP0104206A2
HUP0104206A2 HU0104206A HUP0104206A HUP0104206A2 HU P0104206 A2 HUP0104206 A2 HU P0104206A2 HU 0104206 A HU0104206 A HU 0104206A HU P0104206 A HUP0104206 A HU P0104206A HU P0104206 A2 HUP0104206 A2 HU P0104206A2
Authority
HU
Hungary
Prior art keywords
preparation
pregn
hydroxy
methyl
19nor
Prior art date
Application number
HU0104206A
Other languages
English (en)
Inventor
Peter Huub Gerard Maria Kirchholtes
Gerard Arnoud Jozef Maria Theresia Sas
Original Assignee
Akzo Nobel N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8234220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0104206(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel N.V. filed Critical Akzo Nobel N.V.
Publication of HUP0104206A2 publication Critical patent/HUP0104206A2/hu
Publication of HUP0104206A3 publication Critical patent/HUP0104206A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Abstract

A tal lm ny t rgya nagy tisztas gú készítmény, amely (7a, 17a)-17-hidroxi-7-metil-19-nor-17-pregn-5(10)-én-20-in-3-ont tartalmaz. A tallm ny kiterjed nagy tisztas gú (7a, 17a)-17-hidroxi-7-metil-19-nor-17-pregn-4-én-20-in-3-on készítmény elő llít s ra, és az elj r s olyankészítményt eredményez, amelyben a (7a, 17a)-17-hidroxi-7-metil-19-nor-17-pregn-4-én-20-in-3-on 0,5%-n l kevesebb. A készítményt stabilgyógy szati dózisegységek elő llít s nak forr saként haszn lhatj k. Ó
HU0104206A 1998-10-16 1999-10-11 High purity composition comprising (7alpha,17alpha)- 17-hydroxy- 7-methyl- 19nor-17-pregn-5(10)-en-20-yn-3-one and process for its preparation HUP0104206A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203460 1998-10-16
PCT/EP1999/007768 WO2000023460A1 (en) 1998-10-16 1999-10-11 HIGH PURITY COMPOSITION COMPRISING (7α,17α)- 17-HYDROXY- 7-METHYL- 19-NOR-17-PREGN- 5(10)-EN-20-YN-3-ONE

Publications (2)

Publication Number Publication Date
HUP0104206A2 true HUP0104206A2 (hu) 2002-04-29
HUP0104206A3 HUP0104206A3 (en) 2002-06-28

Family

ID=8234220

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104206A HUP0104206A3 (en) 1998-10-16 1999-10-11 High purity composition comprising (7alpha,17alpha)- 17-hydroxy- 7-methyl- 19nor-17-pregn-5(10)-en-20-yn-3-one and process for its preparation

Country Status (30)

Country Link
US (3) US6969708B1 (hu)
EP (2) EP1275379A3 (hu)
JP (1) JP2002527525A (hu)
KR (3) KR20050003358A (hu)
CN (2) CN100378116C (hu)
AR (1) AR020832A1 (hu)
AT (1) ATE239032T1 (hu)
AU (1) AU763232B2 (hu)
BR (1) BR9914441A (hu)
CA (1) CA2344686C (hu)
CO (1) CO5160271A1 (hu)
CZ (1) CZ298703B6 (hu)
DE (1) DE69907495T2 (hu)
DK (1) DK1121375T3 (hu)
ES (1) ES2197677T3 (hu)
HK (1) HK1039620B (hu)
HU (1) HUP0104206A3 (hu)
ID (1) ID28463A (hu)
IL (1) IL141850A (hu)
NO (1) NO317427B1 (hu)
NZ (1) NZ510501A (hu)
PE (1) PE20001377A1 (hu)
PL (1) PL197870B1 (hu)
PT (1) PT1121375E (hu)
RU (1) RU2220975C2 (hu)
SK (1) SK284569B6 (hu)
TR (2) TR200504091T2 (hu)
TW (2) TW200403251A (hu)
WO (1) WO2000023460A1 (hu)
ZA (1) ZA200101952B (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL356465A1 (en) * 2002-10-04 2004-04-05 ANPHARM Przedsiębiorstwo Farmaceutyczne S.A. METHOD OF MANUFACTURE OF 17beta-HYDROXY-7alpha-METHYL-19-NOR-17alpha-PREGN-5(10)-ENE-20-YNE-3-ONE
TW200418525A (en) * 2002-11-20 2004-10-01 Akzo Nobel Nv Coated pharmaceutical tablets containing Tibolone
GB0304927D0 (en) 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
WO2005117899A1 (en) * 2004-06-02 2005-12-15 Cipla Limited Pharmaceutical composition comprising tibolone and process for procuding the same
LT2662380T (lt) 2005-02-01 2019-03-12 Atnahs Pharma Uk Limited Ibandronato polimorfo a medicininis panaudojimas
DK1848727T3 (da) 2005-02-01 2015-07-20 Hoffmann La Roche Ibandronat polymorf b
WO2006125453A1 (en) * 2005-05-23 2006-11-30 Newchem S.P.A. Process for the preparation of pure crystalline tibolone
CZ300465B6 (cs) * 2007-07-25 2009-05-27 Zentiva, A. S. Zpusob výroby komprimované farmaceutické formulace s obsahem tibolonu
ITMI20130120A1 (it) * 2013-01-25 2014-07-26 Ind Chimica Srl Processo per la preparazione in forma cristallina di tibolone, (7alfa,17alfa)-17-idrossi-7-metil-19-norpregn-5(10)-en-20-in-3-one
US20220046948A1 (en) * 2018-12-17 2022-02-17 Aimmune Therapeutics, Inc. Formulations for egg oral immunotherapy, methods of manufacture, and treatments for egg allergy
CN114409717B (zh) * 2021-12-17 2023-03-17 湖南科益新生物医药有限公司 替勃龙中间体醚化物和替勃龙的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE665514A (hu) * 1964-06-16
CH488682A (de) * 1965-07-30 1970-04-15 Ciba Geigy Verfahren zur Herstellung von 4,9,11-Trienen der 19-Nor-androstanreihe
NL146838B (nl) * 1966-06-24 1975-08-15 Organon Nv Werkwijze voor het bereiden van (delta)5(10)-3- keto-19-norsteroiden.
US3515719A (en) * 1967-03-15 1970-06-02 Upjohn Co 7-methyl-6,19-epoxy steroids of the androstane series
US4701450A (en) * 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
JPH03503414A (ja) * 1988-03-25 1991-08-01 アクゾ・エヌ・ヴエー フッ化物塩を含有する医薬製剤
IE63051B1 (en) * 1989-03-18 1995-03-22 Akzo Nv Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one
ES2134313T3 (es) * 1993-03-05 1999-10-01 Akzo Nobel Nv Utilizacion de derivados de pregnano para el tratamiento de tumores.
CA2159419C (en) 1994-10-17 2006-07-04 Pieter De Haan Solid pharmaceutical composition comprising an excipient capable of binding water
TW448049B (en) * 1997-03-05 2001-08-01 Akzo Nobel Nv Use of a 7Α-methyl-17Α-ethynyl-estrane derivative for the treatment of atherosclerosis
IL123984A (en) * 1997-04-22 2004-09-27 Akzo Nobel Nv Pharmacological dosage units containing tibolone and carrier pharmacy are acceptable

Also Published As

Publication number Publication date
EP1275379A2 (en) 2003-01-15
KR20010080133A (ko) 2001-08-22
DK1121375T3 (da) 2003-08-04
TR200504091T2 (tr) 2006-05-22
ATE239032T1 (de) 2003-05-15
US20040248870A1 (en) 2004-12-09
PL347264A1 (en) 2002-03-25
IL141850A0 (en) 2002-03-10
KR100635018B1 (ko) 2006-10-17
HUP0104206A3 (en) 2002-06-28
PT1121375E (pt) 2003-07-31
CZ2001976A3 (cs) 2001-08-15
CN100378116C (zh) 2008-04-02
NO20011664D0 (no) 2001-04-03
TR200101083T2 (tr) 2001-08-21
KR20050003358A (ko) 2005-01-10
WO2000023460A1 (en) 2000-04-27
AR020832A1 (es) 2002-05-29
CN1322210A (zh) 2001-11-14
PL197870B1 (pl) 2008-05-30
HK1039620A1 (en) 2002-05-03
TW577893B (en) 2004-03-01
CN1769293A (zh) 2006-05-10
AU763232B2 (en) 2003-07-17
US6969708B1 (en) 2005-11-29
NO317427B1 (no) 2004-10-25
PE20001377A1 (es) 2000-12-09
CO5160271A1 (es) 2002-05-30
SK284569B6 (sk) 2005-06-02
ZA200101952B (en) 2002-06-10
BR9914441A (pt) 2001-06-26
DE69907495D1 (de) 2003-06-05
NZ510501A (en) 2003-10-31
ID28463A (id) 2001-05-24
AU6202999A (en) 2000-05-08
EP1121375A1 (en) 2001-08-08
CN100432093C (zh) 2008-11-12
TW200403251A (en) 2004-03-01
IL141850A (en) 2005-11-20
EP1275379A3 (en) 2003-03-26
JP2002527525A (ja) 2002-08-27
DE69907495T2 (de) 2004-05-06
KR20060071897A (ko) 2006-06-27
US20050245496A1 (en) 2005-11-03
CA2344686A1 (en) 2000-04-27
HK1039620B (zh) 2003-08-22
CZ298703B6 (cs) 2007-12-27
EP1121375B1 (en) 2003-05-02
ES2197677T3 (es) 2004-01-01
RU2220975C2 (ru) 2004-01-10
SK4932001A3 (en) 2001-12-03
NO20011664L (no) 2001-04-03
CA2344686C (en) 2009-04-28

Similar Documents

Publication Publication Date Title
AU2125192A (en) New naphthylethlylureas and naphthylethylthioureas, process for the preparation thereof, and pharmaceutical compositions containing them
MY133647A (en) Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
NO2005025I1 (no) Krystalinsk ceftiofurfri syre, fremgangsmate for fremstilling av denne, og farmasoytisk preparat
CA2318128A1 (en) Oral liquid compositions
CA2056066A1 (en) A physical form of n-[4-[5-(cyclopentyloxycarbony)amino-1-methylindol-3yl-methy1]-3-methoxybenzoy1]-2-methlbenzenesulphonamide, processes for its preparation and compositions containing it
JO3404B1 (ar) تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين
IL90912A0 (en) Condensed heterocyclic compounds,their manufacture and pharmaceutical compositions containing them
MY101791A (en) New benzimidazole derivatives
AU649115B2 (en) New heterocycle-substituted alkylamides, process for preparing them and pharmaceutical compositions containing them
HUP9603237A2 (hu) (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzizotiazol-2-il)-butil]-amino-metil}-kromán kristályos hidrokloridja, eljárás előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
AU8976291A (en) New 1,4-disubstituted piperazines, process for the preparation thereof, and pharmaceutical compositions containing them
ZA948669B (en) New pyrazine carboxamide derivatives the preparation thereof and their use in pharmaceutical compositions
HUP0104206A2 (hu) (7alfa,17alfa)-17-Hidroxi-7-metil-19-nor-17-pregn-5(10)-en-20-in-3-ont tartalmazó nagy tisztaságú készítmény és eljárás előállítására
YU211087A (en) Process for obtaining new n-substituted benzimidazolic derivatives
EP1026157A3 (en) Method for the synthesis of huperzine A and analogs thereof and compounds useful therein
DE69804865T2 (de) Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis
MX9603300A (es) Derivados de la 4-sulfonilbenzoilguanidina o la 4-sulfinilbenzoilguanidina.
ES2001875A6 (es) Procedimiento para preparar nuevos derivados de aminoacidos
HUP0102244A2 (hu) Fluid energiával végzett őrlési eljárás és az ehhez alkalmazott berendezés
HUP0105308A2 (hu) Eletriptán-hidrobromid-monohidrát, eljárás az előállítására és a vegyületet tartalmazó gyógyszerkészítmények
AU2003271811A8 (en) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same
HU9303000D0 (en) Aryl-morpholine-derivatives and pharmaceutical compositions containing it and process for production thereof
RU94000064A (ru) Новые 2-циано-3-гидроксипропенамиды, метод их получения и содержащие их фармацевтические композиции
HUP0303319A2 (hu) 9-Dezoxo-9-dihidro-9a-aza-9a-homoeritromicin A és 5-O-dezozaminil-9-dezoxo-9-dihidro-9a-aza-9a-homoeritronolid A 9a-N-[N'-(fenil-szulfonil)karbamoil]-származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
IL130273A (en) N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate, pharmaceutical compositions containing the same and the use thereof for the manufacture of medicaments

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: N.V. ORGANON, NL

Free format text: FORMER OWNER(S): AKZO NOBEL N.V., NL

FD9A Lapse of provisional protection due to non-payment of fees